Clinical Trial Update: MT2017-45: CAR-T Cell Therapy for Heme Malignancies [Phase 2]

View source ↗

Summary

Phase 2 trial MT2017-45 CAR-T cell therapy for hematologic malignancies has an active-not-recruiting status with results posted as of 2026-01-23.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Diffuse Large B-cell Lymphoma

Drugs mentioned

• MT2017-45

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-01-23